ABSTRACTThe Hepatitis B vaccine's safety profile is considered safe, but sometimes neurological complications, like Bell's palsy (acute peripheral facial neuropathy), can occur after its administration. A 35‐year‐old female doctor experienced left‐sided facial weakness and paralysis six days after getting the Hepatitis B vaccine. On examination, she had lower motor neuron facial nerve palsy. After excluding other causes, a diagnosis of Bell's palsy was made following Hepatitis B vaccine. She was treated with corticosteroids, antiviral medication, and physiotherapy, which led to a complete resolution over four weeks. Bell's palsy is still an uncommon potential side effect even though the advantages of the Hepatitis B vaccination exceed the risks. Further investigation is necessary to prove a conclusive link between the vaccine and its neurological side effects.

2022-06-06·Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

[Anti-HBs persistence after primary vaccination with three doses of 5 μg recombinant hepatitis B vaccine among normal and high-responder infants: 10-year of follow-up].

Article

作者: Dou, X ; Zhao, X ; Lyu, J J ; Zhang, Li ; Feng, Y ; Xu, A Q ; Meng, X ; Yan, B Y ; Liang, X F ; Wang, F Z

目的： 分析乙型肝炎疫苗（HepB）初次免疫正常及高应答婴儿初次免疫后10年的抗体持久性及其影响因素。 方法： 于2009年8—9月，以山东省济南、潍坊、烟台和威海市为研究现场，按照随机整群抽样方法，抽取1 838名按照“0-1-6”程序完成5 μg重组酵母HepB初次免疫的正常应答及高应答［乙型肝炎表面抗体（抗-HBs）≥100 mIU/ml］的7~12月龄婴儿为研究对象。基线调查时（T₀），采集研究对象静脉血3 ml，采用化学发光微粒子免疫分析法（CMIA）检测乙肝表面抗体（抗-HBs）、乙肝表面抗原（HBsAg）和乙肝核心抗体（抗-HBc），同时采用自行设计的调查问卷收集婴儿的月龄、性别、出生体重、是否早产、出生胎次、分娩地点以及母亲HBV感染状况等信息。分别于2014年6—7月（随访5年）、2019年6—7月（随访10年）（T₁），采集对象静脉血2 ml，采用CMIA方法检测抗-HBs、抗HBc，对抗-HBs<10 mIU/ml者采用CMIA法检测HBsAg。采用多因素非条件logistic和线性回归模型分析T₁时抗-HBs阳性率和几何平均浓度（GMC）的影响因素。 结果： 1 838名研究对象进行10年随访，共随访到1 359名对象，随访率为73.94%（1 359/1 838）；其中，男童占51.15%（625名）。研究对象抗-HBs阳性率由T₀时的100.00%降为T₁时的53.44%（95%CI：50.59%~56.26%），降幅为46.56%，年均递减率为6.07%；研究对象抗-HBs GMC由T₀时的607.89（95%CI：579.01~642.62）mIU/ml降为T₁时的16.44（95%CI：15.06~18.00）mIU/ml，降幅达97.29%，年均递减率为30.30%。多因素logistic回归模型分析结果显示，与及时接种首针HepB者相比，未及时接种首针HepB者的T₁时抗-HBs 阳性率较低，OR（95%CI）值为0.25（0.07~0.71）；与T₀时GMC<1 000 mIU/ml者相比，GMC≥1 000 mIU/ml者的T₁时抗-HBs 阳性率较高，OR（95%CI）值为2.29（1.76~2.97）。多因素线性回归模型分析结果显示，与及时接种首针HepB者相比，未及时接种首针HepB者的T₁时抗-HBs GMC较低，β（95%CI）值为-0.50（-1.24~0.24）；与T₀时GMC<1 000 mIU/ml者相比，GMC≥1 000 mIU/ml者的T₁时抗-HBs GMC较高，β（95%CI）值为0.81（0.62~1.05）。 结论： 5 μg重组酵母HepB初次免疫正常及高应答婴儿免疫后10年抗体水平有所下降；抗体持久性主要与是否及时接种首针疫苗、初次免疫结束时抗-HBs水平有关联。.

2022-06-01·Journal of Medical Virology4区 · 医学

Immune response to hepatitis B vaccination in human immunodeficiency virus‐positive patients in China: A 2‐year retrospective study

4区 · 医学

Article

作者: Deng, Haohui ; Xiang, Fangfei ; Li, Linghua ; Feng, Qianchang ; Cao, Xin ; Lin, Haowei ; Yu, Weihua ; Wu, Yue

AbstractCurrently, the studies focused on the immune response to hepatitis B vaccination in Chinese human immunodeficiency virus (HIV)‐positive patients are limited. In this study, the participants with an initial hepatitis B surface antibody (HBsAb) titer <10 mIU/ml were assigned to Cohort 1 to receive a standard dose of recombinant hepatitis B vaccine, and participants with an initial HBsAb titer between 10 and 100 mIU/ml were assigned to Cohort 2 to receive a single reinforced recombinant vaccine. In Cohort 1, the immune and high response rates in HIV‐positive patients were 93.4%/81.4%, 87.4%/51.5%, and 83.2%/40.7% at 1–3 months, 1 year, and 2 years postvaccination. Multivariate analysis showed that only age and HIV RNA status at baseline were independent factors related to sustained immune response at 2 years postvaccination. In Cohort 2, the high immune response rates in HIV‐positive patients were 78.8%, 60.6%, and 51.5% at 1–3 months, 1 year, and 2 years postvaccination. The immune or high response rates did not differ between HIV‐positive patients and healthy controls at 1–3 months postvaccination in these two cohorts; however, HBsAb titers were significantly lower in HIV‐positive patients. This study summarized the 2‐year data of immune response to hepatitis B vaccination and analyzed the factors related to sustained immune response at 2 years postvaccination in Chinese HIV‐positive patients.

100 项与 Recombinant hepatitis B vaccine(North China Pharmaceutical Genetech Biotechnology Co. Ltd.) 相关的药物交易

登录后查看更多信息